CANB.Can B CORP
10-Q: Can B Corp. Reports Q3 2024 Results, Shifts Focus to Patent Commercialization Amidst Financial Challenges
Sentiment:
Quarterly Report
Can B Corp. announces its Q3 2024 results, marked by a strategic shift away from hemp operations towards commercializing cannabis patents, while facing significant financial headwinds.
Capital raiseThe company is actively seeking to raise capital through debt and/or equity markets.The company is dependent on third-party loans to fund operations.
Worse than expectedThe company's revenue has significantly decreased compared to the previous year.The company's net loss has increased compared to the previous year.The company's cash and cash equivalents are very low, and it has a negative working capital.
Summary
- Can B Corp. reported its financial results for the third quarter of 2024, ending September 30, 2024.
- The company has shifted its business focus to commercializing and enforcing patents acquired by its subsidiary, Nascent Pharma, LLC.
- This shift comes after the company ceased its hemp operations due to an auction of its assets in March 2024.
- The company's Q3 revenues were $15,269, a significant decrease from $418,957 in the same period last year.
- The net loss for the quarter was $3,262,612, compared to a net loss of $4,165,377 in Q3 2023.
- For the nine months ended September 30, 2024, the company's net loss was $11,452,404, compared to a net loss of $7,931,427 for the same period in 2023.
- The company's cash and cash equivalents stood at $7,879 as of September 30, 2024, with a negative working capital of $10,049,951.
- The company is facing substantial doubt about its ability to continue as a going concern and is relying on third-party loans to fund operations.
- The company is also working to restructure its outstanding debt and raise capital through debt and equity markets.
Sentiment
Score: 2
Explanation: The document paints a very negative picture of the company's current financial situation and future prospects. The shift in business focus is a high-risk strategy, and the company's ability to continue as a going concern is in serious doubt.
Positives
- The company is actively pursuing the commercialization of cannabis patents, which could provide a new revenue stream.
- The company is working to restructure its outstanding indebtedness.
- The company is reestablishing production of the Longevity Brand Superfood drink mix for Brooke Burke Body, Inc.
Negatives
- The company has discontinued its hemp operations, which were a significant source of revenue.
- The company has a negative working capital of $10,049,951.
- The company is facing substantial doubt about its ability to continue as a going concern.
- The company's cash and cash equivalents are very low at $7,879.
- The company is operating with reduced staff in its Duramed division, which has negatively impacted revenues.
- The company has incurred significant losses, with a net loss of $11,452,404 for the nine months ended September 30, 2024.
Risks
- The company's ability to continue as a going concern is highly uncertain.
- The company is dependent on third-party loans to fund operations.
- The company may not be successful in generating additional cash from equity or debt financings.
- The company's new focus on patent commercialization is unproven and may not generate sufficient revenue.
- The company is facing legal challenges related to its debt and the auction of its hemp division assets.
- The company's Duramed division is operating with reduced staff, which could further impact revenues.
Future Outlook
The company's primary focus will be on protecting and commercializing the cannabis patents acquired by Nascent, continuing to collect Duramed receivables, and reestablishing the company's production of the Longevity Brand Superfood drink mix for Brooke Burke Body, Inc. The company is also working to restructure its outstanding indebtedness and raise capital through debt and/or equity markets.
Management Comments
- The Board of Directors concluded that as a result of the impact of the auction conducted by Arena under Article 9 of the Uniform Commercial Code on the hemp division, it is no longer feasible to continue our hemp operations.
- Going forward, our primary focus will be on protecting and commercializing the cannabis patents acquired by Nascent, continuing to collect Duramed receivables and reestablishing the Companys production of the Longevity Brand Superfood drink mix for Brooke Burke Body, Inc.
Industry Context
The shift away from hemp operations and towards patent commercialization reflects a broader trend in the cannabis industry, where companies are increasingly focusing on intellectual property and licensing agreements. The company's financial struggles highlight the challenges faced by many smaller players in the industry, particularly those that have not yet achieved profitability.
Comparison to Industry Standards
- The company's revenue decline and net losses are significantly worse than many of its peers in the cannabis industry, particularly those focused on product sales.
- Companies like Canopy Growth and Aurora Cannabis, while also facing challenges, have significantly higher revenues and more established market positions.
- The shift to patent commercialization is similar to strategies employed by some biotech companies, but the success of this approach is highly dependent on the strength of the patents and the company's ability to enforce them.
- The company's negative working capital and low cash reserves are a major concern, as many companies in the industry maintain a stronger financial position to fund operations and growth.
Legal Proceedings
- The company is involved in a commercial legal action against the company and certain officers by David Weissberg and Donna Marino.
- A vendor of the company filed an amended suit against the company in Florida for monies allegedly owed and civil theft.
- Evexia Plus, LLC filed a complaint against Can B Corp. in a product payment trade dispute.
- Arena Special Opportunities Partners I, LP, Arena Special Opportunities Fund, LP and Arena Investors, LP notified the company of defaults in the performance of its obligations and conducted an auction of certain assets.
- Arena filed a complaint against the company, its subsidiaries and certain officers alleging tortious interference with the auction and seeking a declaratory judgment that the company is in breach of the Arena Notes and the Forbearance Agreement.
Related Party Transactions
- The company has entered into a promissory note with Pat Ferro, a co-founder of the company, with a total amount outstanding of $457,850 as of September 30, 2024.
Stakeholder Impact
- Shareholders are at high risk due to the company's financial instability and the uncertainty of its future.
- Employees may face job insecurity due to the company's restructuring and reduced operations.
- Customers may experience disruptions in product availability due to the company's shift in focus and reduced operations.
- Suppliers and creditors face increased risk of non-payment due to the company's financial difficulties.
Next Steps
- The company will focus on protecting and commercializing the cannabis patents acquired by Nascent.
- The company will continue to collect Duramed receivables.
- The company will reestablish production of the Longevity Brand Superfood drink mix for Brooke Burke Body, Inc.
- The company will work to restructure its outstanding indebtedness.
- The company will seek to raise capital through debt and/or equity markets.
Key Dates
| Date | Description |
|---|---|
| 2005-10-11 | Can B Corp. was originally incorporated as WrapMail, Inc. |
| 2015-10-25 | Can B implemented a legal reorganization resulting in Nascent Pharma Holdings, Inc. owning all of Can B's stock. |
| 2017-05-15 | WrapMail, Inc. changed its name to Canbiola, Inc. |
| 2018-12-28 | Can B Corp. acquired 100% of the membership interests in Pure Health Products, LLC. |
| 2019-02-01 | Duramed began operating. |
| 2020-01-16 | Canbiola, Inc. changed its name to Can B Corp. |
| 2020-12-31 | Date of convertible promissory note (ASOP Note I) with Arena Special Opportunities Partners I, LP. |
| 2020-12-31 | Date of convertible promissory note (ASOF Note I) with Arena Special Opportunities Fund, LP. |
| 2021-05-31 | Date of convertible promissory note (ASOP Note II) with Arena Special Opportunities Partners I, LP. |
| 2021-05-31 | Date of convertible promissory note (ASOF Note II) with Arena Special Opportunities Fund, LP. |
| 2021-08-12 | Date of Equipment Acquisition Agreement with TWS. |
| 2022-01-01 | Date of convertible promissory note (Empire Note) with Empire Properties, LLC. |
| 2022-03-31 | Date of convertible promissory note (BL Note) with Blue Lake Partners, LLC. |
| 2022-04-30 | Date of convertible promissory note (FM Note) with Fourth Man, LLC. |
| 2022-06-30 | Date of convertible promissory note (Alumni Note) with Alumni Capital, LP. |
| 2022-08-31 | Date of convertible promissory note (WN) with Walleye Opportunities Master Fund Ltd. |
| 2023-01-31 | Date of convertible promissory note (Tysadco Note VI) with Tysadco Partners, LLC. |
| 2023-02-27 | Effective date of extension of maturity date of BL Note and FM Note. |
| 2023-03-02 | Date of sale of promissory note to WOMF pursuant to a Securities Purchase Agreement. |
| 2023-05-31 | Date of promissory note issued to WOMF. |
| 2023-09-30 | Date of convertible note issued to ClearThink Capital Partners, LLC. |
| 2023-10-27 | Date of sale of promissory note (the Initial Note) to WOMF. |
| 2023-12-01 | Date of convertible note issued to ClearThink Capital Partners, LLC. |
| 2023-12-31 | Arena agreed to forbear from exercising remedies under the Arena Notes until this date. |
| 2024-02-29 | Date of sale of a promissory note to ClearThink. |
| 2024-02-13 | Date of sale of a promissory note to ClearThink. |
| 2024-03-14 | Auction of the assets of the company's hemp division. |
| 2024-05-31 | Date of Note Extension Agreement with ClearThink. |
| 2024-06-30 | The company shifted its business focus to commercializing and enforcing the patents recently acquired by Nascent Pharma, LLC. |
| 2024-07-29 | Effective date of Consulting Agreement with Vivid Integrated Solutions, LLC. |
| 2024-08-26 | Effective date of Consulting Agreement with Magna Global Ventures, LLC. |
| 2024-08-23 | Date of Secured Demand Promissory Note issued to Pasquale Ferro. |
| 2024-09-30 | End of the reporting period for the Q3 2024 results. |
| 2024-10-25 | Can B implemented a legal reorganization which resulted in NPH owning all of the outstanding stock of Can B. |
| 2024-11-19 | Date of the report. |
Keywords
cannabis patents, hemp operations, financial results, going concern, patent commercialization, debt restructuring, Nascent Pharma, Duramed, working capital, litigation funding
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.